title: Interleukin-4 inhibition of osteoclast differentiation is stronger than that of interleukin-13 and they are equivalent for induction of osteoprotegerin production from osteoblasts.
abstract: Interleukin (IL)-4 and IL-13 are closely related cytokines known to inhibit osteoclast formation by targeting osteoblasts to produce an inhibitor, osteoprotegerin (OPG), as well as by directly targeting osteoclast precursors. However, whether their inhibitory actions are the same remains unclear. The inhibitory effect of IL-4 was stronger than that of IL-13 in an osteoclast-differentiation culture system containing mouse osteoblasts and osteoclast precursors. Both cytokines induced OPG production by osteoblasts in similar time- and dose-dependent manners. However, IL-4 was stronger in direct inhibition that targeted osteoclast precursors. Furthermore, IL-4 induced phosphorylation of signal transducer and activator of transcription-6 (STAT6) at lower concentrations than those of IL-13 in osteoclast precursors. IL-4 but not IL-13 strongly inhibited the expression of nuclear factor of activated T-cells, cytoplasmic 1 (nuclear factor-ATc1), a key factor of osteoclast differentiation, by those precursors. Thus, the activities of IL-4 and IL-13 toward osteoclast precursors were shown to be different in regards to inhibition of osteoclast differentiation, whereas those toward osteoblasts for inducing OPG expression were equivalent.
authors.affiliation: Department of Biochemistry, School of Dentistry, Showa University, Shinagawa, Tokyo, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Yamada
authors.forename: Masamichi
authors.initials: M
authors.lastname: Takami
authors.forename: Tadaharu
authors.initials: T
authors.lastname: Kawawa
authors.forename: Rika
authors.initials: R
authors.lastname: Yasuhara
authors.forename: Baohong
authors.initials: B
authors.lastname: Zhao
authors.forename: Ayako
authors.initials: A
authors.lastname: Mochizuki
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Miyamoto
authors.forename: Tomoo
authors.initials: T
authors.lastname: Eto
authors.forename: Hisataka
authors.initials: H
authors.lastname: Yasuda
authors.forename: Yuko
authors.initials: Y
authors.lastname: Nakamichi
authors.forename: Nacksung
authors.initials: N
authors.lastname: Kim
authors.forename: Takenobu
authors.initials: T
authors.lastname: Katagiri
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Suda
authors.forename: Ryutaro
authors.initials: R
authors.lastname: Kamijo
mesh_terms: D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology; D018920:Coculture Techniques; D004305:Dose-Response Relationship, Drug; D005786:Gene Expression Regulation / Q000187:drug effects; D018793:Interleukin-13 / Q000494:pharmacology*; D015847:Interleukin-4 / Q000494:pharmacology*; D008264:Macrophages / Q000166:cytology; D008297:Male; D051379:Mice; D050778:NFATC Transcription Factors / Q000096:biosynthesis / Q000235:genetics; D010006:Osteoblasts / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D010010:Osteoclasts / Q000166:cytology / Q000187:drug effects*; D053244:Osteoprotegerin / Q000096:biosynthesis* / Q000235:genetics; D053245:RANK Ligand / Q000096:biosynthesis / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics; D011994:Recombinant Proteins / Q000494:pharmacology; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D050800:STAT6 Transcription Factor / Q000378:metabolism
chemical_list: D018793:Interleukin-13; D050778:NFATC Transcription Factors; C494005:Nfatc1 protein, mouse; D053244:Osteoprotegerin; D053245:RANK Ligand; D012333:RNA, Messenger; D011994:Recombinant Proteins; D050800:STAT6 Transcription Factor; C494100:Stat6 protein, mouse; C505689:Tnfsf11 protein, mouse; D015847:Interleukin-4